Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Author： Naidoo Jarushka   Sima Camelia S.   Rodriguez Katherine   Busby Natalie   Nafa Khedoudja   Ladanyi Marc   Riely Gregory J.   Kris Mark G.   Arcila Maria E.   Yu Helena A.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|18|3212-3220

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.18, 2015-09, pp. : 3212-3220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

By Lo Peter C.   Dahlberg Suzanne E.   Nishino Mizuki   Johnson Bruce E.   Sequist Lecia V.   Jackman David M.   Jänne Pasi A.   Oxnard Geoffrey R.  

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2570-2577

Blackwell Publishing

Access to resources Recommend Favorite

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3896-3901

Blackwell Publishing

Access to resources Recommend Favorite

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

By Reckamp Karen L.   Giaccone Giuseppe   Camidge D. Ross   Gadgeel Shirish M.   Khuri Fadlo R.   Engelman Jeff A.   Koczywas Marianna   Rajan Arun   Campbell Alicyn K.   Gernhardt Diana   Ruiz-Garcia Ana   Letrent Stephen   Liang Jane   Taylor Ian   O'Connell Joseph P.   Jänne Pasi A.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1145-1154

Blackwell Publishing

Access to resources Recommend Favorite

Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations

By  

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1613-1628

Bentham Science Publishers

Access to resources Recommend Favorite

Massive Thrombosis of Brachiocephalic Veins and Superior Vena Cava Syndrome in a Patient with Non-Small Cell Lung Cancer Treated with the Epidermal Growth Factor Receptor Inhibitor Erlotinib

By Salmi Raffaella   Gaudenzi Piergiorgio   Filippo Di Todaro   Morandi Pierluigi   Nielsen Ingrid   Manfredini Roberto  

Clinical Drug Investigation, Vol. 27, Iss. 7, 2007-01 ,pp. : 499-503

Adis International

Access to resources Recommend Favorite